

Corrigenda

WHO Classification of Tumours, 5th edition: Central Nervous System Tumours

July 2024 (after 3rd print run)

Updated corrigenda for this volume can be found at <https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Central-Nervous-System-Tumours-2021>.

Summary of corrections:

ICD-O coding of central nervous system tumours (p. 3)

Under the headings “Embryonal tumours” > “Medulloblastomas, histologically defined”, an additional subtype entry has been added as shown.

Original text	Corrected text
Embryonal tumours ... <i>Medulloblastomas, histologically defined</i> 9470/3 Medulloblastoma, histologically defined 9471/3 Desmoplastic nodular medulloblastoma 9471/3 Medulloblastoma with extensive nodularity 9474/3 Large cell medulloblastoma 9474/3 Anaplastic medulloblastoma	Embryonal tumours ... <i>Medulloblastomas, histologically defined</i> 9470/3 Medulloblastoma, histologically defined 9470/3 Classic medulloblastoma 9471/3 Desmoplastic nodular medulloblastoma 9471/3 Medulloblastoma with extensive nodularity 9474/3 Large cell medulloblastoma 9474/3 Anaplastic medulloblastoma

Updated online: Update pending

Updated in print: No (pending next print run)

Astrocytoma, IDH-mutant (p. 19)

In the print version, a reference citation has been added at the end of the *Localization* subsection as shown. In the online version, an incorrect PMID had previously been cited here and has now been corrected as shown.

Original text (print)	Corrected text (print)
Localization ... A genetically distinct form of IDH-mutant astrocytoma has recently been described in the infratentorial compartment.	Localization ... A genetically distinct form of IDH-mutant astrocytoma has recently been described in the infratentorial compartment {187} .
Original text (online)	Corrected text (online)
Localization ... A genetically distinct form of IDH-mutant astrocytoma has recently been described in the infratentorial compartment {1897} .	Localization ... A genetically distinct form of IDH-mutant astrocytoma has recently been described in the infratentorial compartment {187} .

References cited above:

- 187.** Banan R, Stichel D, Bleck A, et al. Infratentorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathol.* 2020 Oct;140(4):569–81. PMID:32776277
- 1897.** Lin KM, Lin SJ, Lin JH, et al. Dysregulation of dual-specificity phosphatases by Epstein-Barr virus LMP1 and its impact on lymphoblastoid cell line survival. *J Virol.* 2020 Jan 31;94(4):e01837-19. PMID:31776277

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Astrocytoma, IDH-mutant (p. 26)

The “greater than” symbol has been corrected to a “greater than or equal to” symbol as shown.

Original text	Corrected text
<p>Diagnostic molecular pathology</p> <p>...</p> <p>Immunohistochemical staining for [...]</p> <p>[top of p. 26:]</p> <p>helps to distinguish true neoplasia from [...]. Given the low frequency of <i>IDH1</i> and <i>IDH2</i> mutations in CNS WHO grade 4 gliomas arising in patients aged > 55 years, sequencing analysis need not follow a negative IDH1 p.R132H immunostain in this patient population.</p>	<p>Diagnostic molecular pathology</p> <p>...</p> <p>Immunohistochemical staining for [...]</p> <p>[top of p. 26:]</p> <p>helps to distinguish true neoplasia from [...]. Given the low frequency of <i>IDH1</i> and <i>IDH2</i> mutations in CNS WHO grade 4 gliomas arising in patients aged ≥ 55 years, sequencing analysis need not follow a negative IDH1 p.R132H immunostain in this patient population.</p>

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Posterior fossa group A (PFA) ependymoma (p. 174)

The final sentence of the *Prognosis and prediction* subsection has been corrected as shown.

Original text	Corrected text
<p>Prognosis and prediction</p> <p>... The prognostic significance of an H3 p.K28me3 (K27me3) mutation in a small proportion of PFA ependymomas is unknown.</p>	<p>Prognosis and prediction</p> <p>... The prognostic significance of an H3 p.K28 (K27) mutation in a small proportion of PFA ependymomas is unknown {1065,2765}.</p>
<p>References added above:</p> <p>1065. Gessi M, Capper D, Sahm F, et al. Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathol.</i> 2016 Oct;132(4):635–7. PMID:27539613</p> <p>2765. Ryall S, Guzman M, Elbabaa SK, et al. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. <i>Childs Nerv Syst.</i> 2017 Jul;33(7):1047–51. PMID:28623522</p>	

Updated online: November 2022

Updated in print: Yes (in 2nd print run), March 2022

Myxopapillary ependymoma (p. 184)

“≥ 2 mitoses/mm²” has been corrected to “≥ 5 mitoses/mm²” as shown.

Original text	Corrected text
Histopathology ... <i>[top of p. 184:]</i> by PAS and Alcian blue positivity [...]. Exceptional examples termed “anaplastic myxopapillary ependymomas” manifest regional hypercellularity and reduced mucin in association with at least two of the following features: ≥ 2 mitoses/mm ² , Ki-67 labelling index ≥ 10%, microvascular proliferation, and spontaneous necrosis ...	Histopathology ... <i>[top of p. 184:]</i> by PAS and Alcian blue positivity [...]. Exceptional examples termed “anaplastic myxopapillary ependymomas” manifest regional hypercellularity and reduced mucin in association with at least two of the following features: ≥ 5 mitoses/mm ² , Ki-67 labelling index ≥ 10%, microvascular proliferation, and spontaneous necrosis ...

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Medulloblastoma, histologically defined (p. 213)

In the *ICD-O coding* subsection, an additional entry has been added as shown.

Original text	Corrected text
ICD-O coding 9470/3 Medulloblastoma, histologically defined 9471/3 Desmoplastic nodular medulloblastoma 9471/3 Medulloblastoma with extensive nodularity 9474/3 Large cell medulloblastoma 9474/3 Anaplastic medulloblastoma	ICD-O coding 9470/3 Medulloblastoma, histologically defined 9470/3 Classic medulloblastoma 9471/3 Desmoplastic nodular medulloblastoma 9471/3 Medulloblastoma with extensive nodularity 9474/3 Large cell medulloblastoma 9474/3 Anaplastic medulloblastoma

Updated online: Update pending

Updated in print: No (pending next print run)

Primary diffuse large B-cell lymphoma of the CNS (p. 351)

A minor typographical error has been corrected as shown.

Original text	Corrected text
Localization Primary CNS-DLBLECs are solitary brain lesions in 65% of cases ...	Localization Primary CNS-DLBCLs are solitary brain lesions in 65% of cases ...

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Germ cell tumours of the CNS (p. 384)

A reference citation has been corrected as shown.

Original text	Corrected text
Etiology Germline variants of the <i>JMJD1C</i> gene, which encodes a jumonji domain–containing histone demethylase, have been associated with a heightened risk of CNS germ cell tumours in Japanese people {1762}.	Etiology Germline variants of the <i>JMJD1C</i> gene, which encodes a jumonji domain–containing histone demethylase, have been associated with a heightened risk of CNS germ cell tumours in Japanese people {3374}.
References cited above: 1762. Kuroki S, Akiyoshi M, Tokura M, et al. JMJD1C, a JmjC domain-containing protein, is required for long-term maintenance of male germ cells in mice. <i>Biol Reprod.</i> 2013 Oct 17;89(4):93. PMID:24006281 3374. Wang L, Yamaguchi S, Burstein MD, et al. Novel somatic and germline mutations in intracranial germ cell tumours. <i>Nature.</i> 2014 Jul 10;511(7508):241–5. PMID:24896186	

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Adamantinomatous craniopharyngioma (p. 394, 396)

“Xp28” has been corrected to “Xq28” as shown.

Original text	Corrected text
Pathogenesis ... Adamantinomatous craniopharyngiomas are characterized by [...]. Recurrent focal deletions of Xp28 have been described in a subset of samples from male patients, and other recurrent gains have also been described ...	Pathogenesis ... Adamantinomatous craniopharyngiomas are characterized by [...]. Recurrent focal deletions of Xq28 have been described in a subset of samples from male patients, and other recurrent gains have also been described ...
Prognosis and prediction ... Overall survival rates [...]. Although there are few studies of molecular features predictive of worse outcome, tumours with <i>CTNNB1</i> p.T41 mutations or focal deletions of Xp28 may be associated with a worse outcome ...	Prognosis and prediction ... Overall survival rates [...]. Although there are few studies of molecular features predictive of worse outcome, tumours with <i>CTNNB1</i> p.T41 mutations or focal deletions of Xq28 may be associated with a worse outcome ...

Updated online: November 2022

Updated in print: Yes (in 3rd print run), December 2022

Tuberous sclerosis (online version only)

The source information for Box #16788 was missing in the online version (it appears correctly in all print runs of the print version). The source should be listed as follows:

Adapted, with permission from Elsevier, from: Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol*. 2013 Oct;49(4):243–54. PMID:24053982

Updated online: Update pending

Updated in print: n/a – This error was present in the online version only